Administrative Core

CORT的使命是通过利用新的治疗方法， 生物信息学方法与发达的鼠和人类实验能力。这 预计技术整合将更灵活地将新的科学机会转化为临床应用， 应用. CORT行政核心（AC）建议管理一种创新模式， 合作研究项目（CRP）将作为一个中心枢纽， 工作从2个高度互动的研究核心，以实验测试假设和新发现的 途径特异性和重新用途的FDA药物线索。AC将通过以下目标实现这一目标：1. 召集内部咨询委员会和外部咨询委员会，a）制定和应用 CRP、每个核心和P&F项目的问责制度，B）管理Go-NoGo迭代 关于CORT资源利用的算法决策过程，以及c）协调患者群组 资产和监管合规性; 2.提供CORT的财务管理; 3.分支出令人振奋的新 通过强大的试点和可行性（P&F）计划从CORT调查结果中得出的发展; 4.组织 并宣传将CORT和社区研究人员聚集在科学场所的丰富活动 交流思想和新技术。 AC领导层不仅将与实验室科学家密切合作，还将与领导层和 Cleveland地区研究平台的程序员，以推进转化医疗保健 （CLEARPATH），一个综合性的研究数据库，包含来自所有3个主要领域的有限数据集贡献 克利夫兰医疗系统。CLEARPATH将创建连接的数据（例如，生物标本结果，EMR 临床表型、“组学数据"）以及整个系统中的单人记录， 在聚合数据集中进行发现和验证。这种方法将使我们能够初步验证 银屑病队列亚组、混合组学途径和药物线索由Cores和CRP确定。除了 作为研究的信息渠道和促进者，AC还促进了皮肤研究 环境银屑病及其共病和相关条件通过丰富的计划。因此， AC在研究研讨会的设计和规划以及招募潜在的P&F计划方面发挥重要作用 具有创新技术和/或CORT补充研究专长的受助人。 将临床前建模核心（PMC）与应用Meta相结合的跨学科方法 “组学核心”（AMC）利用人工智能、数据挖掘、网络技术和 机器学习查询可用的交互网络和高度注释的集成电子医疗 记录（EMRi）具有很强的创新性。AC的积极参与将有助于成功 实现更广泛的目标，确定新的银屑病途径和重新用途的批准药物。

The mission of the CORT is to advance therapy for psoriasis and related comorbidities by leveraging new bioinformatic methodologies with well-developed murine and human experimentation capabilities. This technology concatenation is expected to more nimbly translate new scientific opportunities into clinical applications. The CORT Administrative Core (AC) proposes to manage an innovative model wherein a collaborative research project (CRP) will serve as the central hub that will iterate significant bi-directional work from 2 highly interactive research cores to experimentally test hypotheses and newly identified pathway specific and repurposed FDA drug leads. The AC will accomplish this goal through its Aims to: 1. Convene an Internal Advisory Committee and an External Advisory Board which a) develops and applies accountability metrics for the CRP, each Core, and the P&F projects, b) manages a Go-NoGo iterative algorithmic decision-making process regarding CORT resource utilization and c) coordinates patient cohort assets and regulatory compliance; 2. Provide fiscal management of the CORT; 3. Branch out exciting new developments deriving from CORT findings through a robust Pilot & Feasibility (P&F) program; 4. Organize and advertise Enrichment Activities that bring CORT and Community researchers together in scientific venues to exchange ideas and new technologies. The AC leadership will work closely not only with lab scientists, but also with the leadership and programmers of the CLEveland Area Research Platform for Advancing Translational Healthcare (CLEARPATH), a comprehensive research database with Limited Data Set contribution from all 3 major Cleveland healthcare systems. CLEARPATH will create connected data (e.g., Biospecimen results, EMR clinical phenotype, `Omics data) as well as a Single person record across the system, enabling research cohort discovery and validation across the aggregate dataset. This approach will allow us to preliminarily validate psoriasis cohort subsets, mix `omic pathways and drug leads identified by the Cores and CRP. In addition to its roles as an information conduit and facilitator for research, the AC also promotes the cutaneous research environment for psoriasis and its comorbid and related conditions through enrichment programs. As such, the AC is instrumental in the design and planning of research symposia, and recruiting potential P&F program recipients with innovative technologies and/or complementary research expertise to the CORT. The cross-disciplinary approach of combining a Preclinical Modeling Core (PMC) with an Applied Meta `Omics Core (AMC) that takes advantage of artificial intelligence, data mining, network techniques and machine learning to query available interaction networks and highly annotated integrated electronic medical records (EMRi) is highly innovative. The active engagement of the AC will be instrumental for the successful achievement of the broader goal of identifying new psoriasis pathways and repurposed approved drugs.